NCT06135350招募中2 期
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of the Drug Fluorothiazinone (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on Mechanical Ventilation
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation2 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2023年11月6日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 234
- 试验地点
- 2
- 主要终点
- MV-associated pneumonia caused by gram-negative bacteria (72-120 hours from the moment of tracheal intubation and the start of the MV)
研究概览
简要总结
This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation of patients on mechanical ventilation.
The main objectives of this study are:
- Evaluation of the clinical and antibacterial efficacy of the drug Fluorothiazinone in combination with standard measures for the prevention of nosocomial infections compared to placebo in combination with standard measures for the prevention of nosocomial infections for the prevention of nosocomial infections caused by bacterial gram-negative flora in patients on mechanical ventilation.
- Evaluation of the safety and tolerability of the drug Fluorothiazinone in patients on mechanical ventilation.
- Evaluation of the pharmacokinetics (in whole blood) of the drug Fluorothiazinone with a single daily dose of 2400 mg/day.
Researchers will compare results for the treatment and the placebo arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's written consent to participate in the study in accordance with the current legislation or the decision of the board in case of absence of consciousness of the patient.
- •Patients are at least 18 years old, male and female.
- •Patients who are in the ICU (intensive care unit).
- •Patients with:
- •Laboratory confirmed SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus-2) on screening (a patient's coronavirus infection can be confirmed either before admission to the hospital (for outpatient treatment) or when admitted to the hospital) by RT-PCR (reverse transcription polymerase chain reaction) AND severe community-acquired pneumonia in ICU with evidence of viral lung injury and symptoms of respiratory failure:
- •SpO2 (peripheral oxygen saturation) ≤ 93%;
- •Lung changes of 3rd- to 4th-degree according to CT (results of computed tomography), consistent with viral involvement; OR 4.
- •Acute stroke; OR 4.
- •Acute heart failure: Cardiogenic shock of any cause, pulmonary edema, or acute decompensated chronic heart failure.
- •Patients who have been on ALV (artificial lung ventilation) for no more than 12 hours.
- •Patients who are according to the investigator are at high risk to be transferred to ALV within 72 hours of the initiation of the therapy.
- •All women of childbearing age and men with partners of childbearing age should agree to use an effective contraceptive methods (e.g., implants, infections, combination oral contraceptives, intrauterine device, abstinence, vasectomy or vasectomy partner) during the entire study.
排除标准
- •The patient was not switched to ALV within 72 hours (3 days) after receiving the investigational drug.
- •People who have a bloodstream infection, identified during the screening.
- •A patient may terminate his/her participation in the study at any time for any reason and without any explanation.
- •The investigator may also decide to terminate the patient's participation at any time if it is required due to the patient's condition.
- •The sponsor or the regulator may also request the trial to be terminated early, either due to how the trial was conducted, or due to application safety data, or other reasons.
- •The main reasons why the patient may withdraw from the study are:
- •Refusal of the patient to participate in the study;
- •Development of an AE (adverse event) / SAE (serious adverse event) that prevents further study participation;
- •The occurrence of concomitant somatic diseases / symptoms or exacerbation of chronic diseases not related to the investigational drug (at the discretion of the medical investigator).
研究组 & 干预措施
Treatment arm
Experimental
干预措施: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day (Drug)
Placebo arm
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
MV-associated pneumonia caused by gram-negative bacteria (72-120 hours from the moment of tracheal intubation and the start of the MV)
时间窗: Throughout the therapy period (14 days).
The proportion of patients in the study groups without clinically and microbiologically confirmed MV-associated pneumonia caused by gram-negative bacteria, which developed no earlier than 72 hours (3 days) and no later than 120 hours (5 days) from the moment of tracheal intubation and the start of the MV, in the absence of signs of pulmonary infection at the time of intubation.
次要结局
- Time from the beginning of the MV to the development of urinary tract infection(Throughout the therapy period (14 days).)
- Proportion of patients who have gram-negative bacteria(Throughout the therapy period (14 days).)
- Proportion of patients with septic complications(Throughout the therapy period (14 days).)
- Proportion of patients who developed urinary tract infection(Throughout the therapy period (14 days).)
- Time from the beginning of the MV to the development of MV-associated pneumonia(Throughout the therapy period (14 days).)
- Time from the beginning of the MV to the development of a bloodstream infection(Throughout the therapy period (14 days).)
- Proportion of patients who developed a bloodstream infection (after the patient was transferred to the MV)(Throughout the therapy period (14 days).)
- The proportion of fatal outcomes(Throughout the therapy period (14 days).)
- Proportion of patients who developed a bloodstream infection (during the entire period of therapy)(Throughout the therapy period (14 days).)
- Proportion of patients who did not develop MV-associated pneumonia(Throughout the therapy period (14 days).)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)Axial SpondyloarthritisNCT06333210Biocad421
已完成
2 期
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyRheumatoid ArthritisNCT01242488UCB Pharma221
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis PatientsCystic FibrosisNCT02190604Novartis Pharmaceuticals153
已完成
1 期
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseAlzheimer's DiseaseNCT02094729Eisai Co., Ltd.26
已完成
2 期
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in AdultsAllergic RhinitisNCT00604123Johnson & Johnson Pharmaceutical Research & Development, L.L.C.74